A perspective on Australia's national medicines policy

Canadian Journal of Clinical Pharmacology

Volumn 11, Issue 1, 2004, Pages

  Tett, Susan E ^a  

^a NONE

Author keywords

Medicines policy; Prescription drug policy; Quality use of medicines

Indexed keywords

SIMVASTATIN;

ARTICLE; AUSTRALIA; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG INDUSTRY; DRUG QUALITY; DRUG SAFETY; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE POLICY; HEALTH CARE SYSTEM; PRESCRIPTION; PUBLIC HEALTH SERVICE; PUBLICATION; QUALITY CONTROL; DRUG CONTROL; HEALTH INSURANCE; HUMAN; INTERNET; LEGAL ASPECT; STANDARD;

AUSTRALIA; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; HEALTH POLICY; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; INTERNET;

EID: 19544389460     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Birkett DJ, Mitchell AS, McManus P. A cost-effectiveness approach to drug subsidy and pricing in Australia. Health Aff (Millwood) 2001;20(3):104-14.
2. Sketris IS, Hill S. The Australian national publicly subsidized Pharmaceutical Benefits Scheme: Any lessons for Canada? Canadian Journal of Clinical Pharmacology 1998;5(2):111-118.
3. Dalton A. Australia's pharmaceutical benefits system: flawed but improving, and better than anywhere else. Aust Health Rev 2001;24(2):7-14.
4. Hailey D. Australian economic evaluation and government decisions on pharmaceuticals, compared to assessment of other health technologies. Soc Sci Med 1997;45(4):563-81.
5. Henry DA. The Australian Guidelines for subsidisation of pharmaceuticals. Pharmacoeconomics 1992;2(5):422-6.
6. Hill SR, Mitchell AS, Henry DA. Problems with the interpretation of pharmacoeconomic analyses: a review of submissions to the Australian Pharmaceutical Benefits Scheme. Jama 2000;283(16):2116-21.
7. Henry DA, Birkett DJ. Changes to the Pharmaceutical Benefits Advisory Committee. Med J Aust 2001;174(5):209-10.
8. Hindle D. Are Australia's drugs too cheap for our own good? Aust Health Rev 2001;24(2):4-6.
9. McManus P, Birkett DJ, Dudley J, Stevens A. Impact of the Minimum Pricing Policy and introduction of brand (generic) substitution into the Pharmaceutical Benefits Scheme in Australia. Pharmacoepidemiol Drug Saf 2001;10(4):295-300.
10. Walker A. Distributional impact of higher patient contributions to Australia's Pharmaceutical Benefits Scheme. Aust Health Rev 2000;23(2):32-46.
11. Lexchin J. A National Pharmacare Plan: Combining Efficiency and Equity. Ottawa: Canadian Centre for Policy Alternatives; 2001 March 2001. Report No.: ISBN: 0-88627-258-0.
12. Morgan SG. Issues for Canadian Pharmaceutical Policy. Health Policy Research Unit Discussion Paper Series. Vancouver: The University of British Columbia; 1997 February 1997. Report No.: HPRU 97:5D.
13. Angus DE, Karpetz HM. Pharmaceutical policies in Canada. Issues and challenges. Pharmacoeconomics 1998;14(Suppl 1):81-96.
14. Denig P, Haaijer-Ruskamp FM. Do physicians take cost into account when making prescribing decisions? Pharmacoeconomics 1995;8(4):282-90.